Previous reports have demonstrated the efficacy of cyclosporine for thrombocytopenia in TAFRO syndrome, suggesting that inhibition of IL-2 may improve thrombocytopenia [8, 9]. This evidence concerns the gene IL2 and Castleman-Kojima disease.